NCT03110562 2024-08-21
BOSTON
Karyopharm Therapeutics Inc
Phase 3 Completed
Clinical Trials
30 trialsNCT02654990 2024-07-12
PANORAMA_3
pharmaand GmbH
Phase 2 Completed
NCT01913730 2023-12-13
Maintenance Therapy With Subcutaneous Bortezomib
European Myeloma Network B.V.
Phase 2 Completed
NCT04173585 2023-03-27
TEAM
University Hospital Heidelberg
Phase 2 Completed
NCT00773838 2021-04-01
MK-0683-095
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00708292 2020-12-17
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Novartis
Phase 1/2 Completed
NCT00903968 2020-06-02
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01497093 2020-04-07
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT00440726 2020-02-19
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Completed
NCT02290431 2019-11-18
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Novartis
Phase 2 Completed
NCT00038571 2018-10-31
Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00201877 2018-03-12
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00401011 2018-02-23
Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients
AEterna Zentaris
Phase 1/2 Completed
NCT01083602 2017-12-21
MACS1271
Novartis
Phase 2 Completed
NCT01359657 2016-03-16
Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1 Completed
NCT00547534 2015-08-06
BVR
University of Rochester
Phase 2 Completed
NCT01160484 2015-05-04
Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma
Oncotherapeutics
Phase 2 Completed
NCT00383474 2015-04-15
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Phase 1 Completed
NCT00994500 2013-07-02
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00651781 2013-02-28
Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
PETHEMA Foundation
Phase 1/2 Completed
NCT00536575 2013-02-27
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00335348 2013-01-09
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT00652041 2011-09-19
TaCyDexVMP7
PETHEMA Foundation
Phase 4 Completed
NCT00752518 2011-05-17
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
Janssen Pharmaceutical K.K.
Phase 1/2 Completed
NCT00602511 2011-02-09
Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma
Nordic Myeloma Study Group
Phase 3 Completed
NCT00509379 2011-01-28
LYM-2023
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase 2 Completed
NCT00382954 2010-09-29
Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
University of Kentucky
Phase 1 Completed
NCT00080405 2009-03-27
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed